Drug Research
Bristol-Myers Squibb Enters into New Collaboration with Johns Hopkins Focused on Immuno-Oncology Research
Bristol-Myers Squibb Company announced that the company has entered into a five-year research collaboration with the Johns Hopkins University. The collaboration is designed to identify mechanisms of response and resistance in patients whose cancer is being...
Drug Research
AdAlta licenses Alzheimer’s disease-specific shark antibodies to Crossbeta Biosciences for therapeutic and diagnostic development
AdAlta Limited a biotechnology company specialising in the discovery and development of protein-based therapeutics, and Crossbeta Biosciences, a biotechnology company with unique technology for therapeutic and diagnostic use in neurodegenerative disorders announced their commercialisation agreement. ...
Drug Research
Lonza Holds Grand Opening for State-of-the-Art Drug Product Services Labs
Lonza, a global leader in chemical and biological manufacturing, held the grand opening of its state-of-the-art pharmaceutical Drug Product Services laboratories in the Stücki Science Park Basel (CH). Scientists in the new 1300 m2 facility will focus initially on...
Drug Research
Takara Bio USA Inc to Supply Single-Cell RNA-Seq Kit for the Allen Cell Types Database
Takara Bio USA Inc announced that its SMART-Seq v4 Ultra Low Input RNA Kit for Sequencing has been selected for the development of gene expression profiles of individual brain cells as part of the Allen Cell Types Database, a...
Drug Research
Sun Pharma Announces US Launch of Authorized Generics for Benicar®, Benicar HCT® , Azor® and Tribenzor®
Sun Pharmaceutical Industries Ltd announced that its wholly owned subsidiary has launched in US, the Authorized Generic (AG) versions for all strengths of: Olmesartan Medoxomil tablets – therapeutic equivalent of Daiichi Sankyo Inc.’s Benicar® (olmesartan...
Drug Research
Antihypertensive drug Micatrio combination tablets launch in Japan
Nippon Boehringer Ingelheim Co., Ltd. and Astellas Pharma Inc. announced that the companies have newly launched “Micatrio®Combination Tablets,” a combination drug of “Micardis® Tablets” (AT1 receptor blocker ), long-acting calcium channel blocker (CCB) amlodipine besylate and the thiazide diuretic...
Drug Research
Teva and Celltrion Announce Exclusive Biosimilar Commercial Partnership
Teva Pharmaceutical Industries Ltd and Celltrion Healthcare announce that the companies have entered into an exclusive partnership to commercialize two of Celltrion’s mAb biosimilar candidates in the U.S. and Canada. CT-P10 is a proposed mAb biosimilar to Rituxan® (rituximab)....
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
